logo
Share SHARE
FONT-SIZE Plus   Neg

Galena Announces Collaboration With Genentech/Roche, Henry Jackson Foundation

Galena Biopharma, Inc. (GALE) announced a clinical development collaboration with Genentech/Roche and Henry Jackson Foundation for the Advancement of Military Medicine to develop NeuVax in combination with Herceptin in adjuvant breast cancer patients currently not eligible for Herceptin therapy.

As per the terms of the collaboration, Genentech and Galena will sponsor a randomized, blinded multicenter Phase 2 clinical study in adjuvant breast cancer in around 300 patients, scheduled to be initiated in the first half of 2012. Clinical studies presented by Galena Biopharma at the American Society of Clinical Oncology meeting in June 2011 demonstrated promising results of NeuVax in combination with Herceptin in preventing breast cancer recurrences.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Dell Inc. decided to end its Venue brand Android tablets and will focus on Windows 10 2-in-1 devices. There will be no operating system upgrades for Venue, however it will continue active warranty and service contract. Tech giant Apple Inc. has developed a new technology that will prohibit audiences using their iPhones to record concerts. The Cupertino, California-based company has secured a patent in the US for its new technology. The technology uses infrared signals to shut down cameras on audience members' smartphones. The... Snacks giant Mondelez International Inc. (MDLZ) made a takeover bid of $23 billion to acquire chocolate behemoth Hershey Co. (HSY) that would create the world's largest chocolate company. Nevertheless, shares of Hershey jumped over 15 percent after the company revealed that it has rejected the offer. "The...
comments powered by Disqus
Follow RTT